Key facts
- Notable investors include Japan External Trade Organization, BioAdvance Capital (Conshohocken), Advanced Regenerative Manufacturing Institute, Johns Hopkins Technology Ventures, Johns Hopkins University.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Agnos Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Agnos Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Agnos Therapeutics
Developer of a mutation-agnostic retinal cell therapy designed to restore vision for inherited blindness. The company utilizes induced pluripotent stem cell technology to create retinal cells that function independently of a patient's specific genetic mutation, providing a universal approach to treating various forms of inherited blindness through a proprietary regenerative process, enabling healthcare professionals to restore sight in patients with various genetic forms of retinal blindness.
- Sector
- Healthcare
- HQ
- Baltimore, MD, United States
- Founded
- 2025
- Website
- agnostx.com/
- Ownership
- Privately Held (backing)
Agnos Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Agnos Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Agnos Therapeutics in its N-PORT filings yet. We sweep new filings monthly.